Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors
Matteo Simonelli(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Luca Di Tommaso(Humanitas University), Luca Rubino(Fondazione Humanitas per la Ricerca), Rita De Sanctis(Humanitas University), Matteo B. Suter(Ospedale di Circolo e Fondazione Macchi), Massimo Roncalli(Fondazione Humanitas per la Ricerca), Fabio De Vincenzo(Humanitas University), Paolo Andrea Zucali(Humanitas University), Lorenza Rimassa(Humanitas University), Monica Bertossi(Humanitas University), Elena Lorenzi(Humanitas University), Matteo Perrino(IRCCS Humanitas Research Hospital), Luca Mancini(University of Milan), Laura Giordano(Istituti di Ricovero e Cura a Carattere Scientifico), Giovanna Masci(Humanitas University), Giuseppe Fattuzzo, Monica Zuradelli(Humanitas University)
Cited by 13
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670